Bluebird Bio

Bluebird BioBluebird Bio
Bluebird Bio

Bluebird Bio

Gene therapy company developing transformative treatments for severe genetic diseases.

1992Active137Somerville, United States
Rate

About

Genetix Biotherapeutics, formerly Bluebird Bio, develops and commercializes one-time administered genetic therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. These therapies treat the underlying cause of rare genetic diseases by modifying a patient's own blood stem cells to restore gene function. The company is focused on commercial execution, scaling patient access, and improving the treatment experience.

Technology stack

detected 2026-07-14
Email
Hosting
Stack
Analytics
Cookie consent
Hiring
Cloud
2
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Bluebird Bio do?

Genetix Biotherapeutics, formerly Bluebird Bio, develops and commercializes one-time administered genetic therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. These therapies treat the underlying cause of rare genetic diseases by modifying a patient's own blood stem cells to restore gene function. The company is focused on commercial execution, scaling patient access, and improving the treatment experience.

How much funding has Bluebird Bio raised?

Bluebird Bio has raised a total of $1.0B in funding. The most recent round on record is Series D.

Where is Bluebird Bio headquartered?

Bluebird Bio is headquartered in Somerville, United States.

When was Bluebird Bio founded?

Bluebird Bio was founded in 1992.

What industry does Bluebird Bio operate in?

Bluebird Bio operates in Biotech, MedTech, HealthTech, Genomics, Drug Discovery, Clinical Trials.

How many employees does Bluebird Bio have?

Bluebird Bio has approximately 137 people on record.

What is Bluebird Bio's revenue?

StartupHub estimates Bluebird Bio's annual revenue at $14.7M (range $8.1M to $58.9M, 64% confidence), based on comparable companies in the sector.

What is Bluebird Bio's valuation?

StartupHub estimates Bluebird Bio's effective valuation at $4.0B (range $2.5B to $6.0B, 10% confidence), based on comparable companies in the sector.